Approval paves the way for expansion in North America’s growing vascular access market, with innovative SlipStream technology designed to simplify catheter insertion and enhance patient care
Dr. Quirk said the program’s mechanism offers a targeted approach to disrupted brain signaling in compulsivity-related disorders
Pharmaceutical R&D veteran brings over 20 years of expertise in formulation development, ANDA filings, and regulated-market product innovation to strengthen MSN Laboratories’ global growth ambitions
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
